Literature DB >> 9796968

Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas.

S H Kim1, J J Lewis, M F Brennan, J M Woodruff, M Dudas, C Cordon-Cardo.   

Abstract

Binding of G1 cyclins to cyclin-dependent kinases leads to phosphorylation of the retinoblastoma protein and progression through G1 and S phases of the cell cycle. Overexpression of cyclins is thought to deregulate this process and has been noted in many human malignancies. This study was conducted to assess patterns of expression and potential gene amplification of the G1 cyclins in 84 patients affected with extremity soft-tissue sarcomas. Sixty cases were primary tumors, whereas the remaining 24 cases were locally recurrent lesions. There were 58 high-grade and 26 low-grade tumors. Immunohistochemical analyses were conducted using antibodies to cyclins D1, E, and A. Southern blot analysis was performed on DNA available from 53 of 84 patients with a cyclin D1-specific probe. Cyclin D1 overexpression was noted in 23 of 79 informative cases (29%), whereas cyclin E was found overexpressed in 26 of 80 cases (33%) and cyclin A overexpression was observed in 9 of 81 cases (11%). Overexpression of cyclins D1, E, or A each correlated significantly with high tumor grade (P <0.05). On multivariate analysis, neither cyclin E nor cyclin A were significant predictors of outcome. However, overexpression of cyclin D1 was significantly associated with worse overall survival for the entire group as well as in the subset of high-grade lesions (P <0.05), notwithstanding the relatively short follow-up time (mean, 2.4 years). Nevertheless, the presence of a significant association between laboratory data and outcome implies that the study is adequately powered. Furthermore, none of the cases demonstrated CCND1 gene amplification. These data support the concept that cyclin D1 overexpression determines the evolution of a particularly aggressive subset of these lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796968

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Exploration of the APC/beta-catenin (WNT) pathway and a histologic classification system for pulmonary artery intimal sarcoma. A study of 18 cases.

Authors:  A Gaumann; B Bode-Lesniewska; D R Zimmermann; J C Fanburg-Smith; C J Kirkpatrick; F Hofstädter; M Woenckhaus; R Stoehr; E C Obermann; W Dietmaier; A Hartmann
Journal:  Virchows Arch       Date:  2008-09-20       Impact factor: 4.064

2.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

Authors:  Axel Hoos; Alexander Stojadinovic; Bhuvanesh Singh; Maria E Dudas; Denis H Y Leung; Ashok R Shaha; Jatin P Shah; Murray F Brennan; Carlos Cordon-Cardo; Ronald Ghossein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.

Authors:  Irene Y Cheung; Yi Feng; Andrew Vickers; William Gerald; Nai-Kong V Cheung
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Assessment of cyclin D1 overexpression as a prognostic factor in soft tissue sarcomas: role of laparoscopy and core needle biopsy.

Authors:  M Musella; F Fazioli; S Lombardi; C I Servodio; C De Martino; V Iacono; F Cigala; R Jovino
Journal:  Surg Endosc       Date:  2005-05-12       Impact factor: 4.584

5.  Prognostic role of Rb, p16, Cyclin D1 proteins in soft tissue sarcomas.

Authors:  Byoung Yong Shim; Jinyoung Yoo; Yeon-Soo Lee; Young Sun Hong; Hoon-Kyo Kim; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

6.  [Diagnostics and treatment strategies for soft tissue sarcomas].

Authors:  G Taeger; S Ruchholtz; J Schütte; D Nast-Kolb
Journal:  Unfallchirurg       Date:  2004-07       Impact factor: 1.000

7.  Head and neck soft tissue sarcoma.

Authors:  A S Aljabab; R W Nason; R Kazi; K A Pathak
Journal:  Indian J Surg Oncol       Date:  2012-03-06

8.  Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.

Authors:  Ronald A Ghossein; Nora Katabi; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-06-17       Impact factor: 5.958

9.  Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater.

Authors:  Daniel Baumhoer; Inti Zlobec; Luigi Tornillo; Wolfgang Dietmaier; Peter H Wuensch; Arndt Hartmann; Fausto Sessa; Petra Ruemmele; Luigi M Terracciano
Journal:  Virchows Arch       Date:  2008-10-21       Impact factor: 4.064

10.  Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.

Authors:  Yan Shi; Zhi Rong Qian; Sui Zhang; Wanwan Li; Yohei Masugi; Tingting Li; Jennifer A Chan; Juhong Yang; Annacarolina Da Silva; Mancang Gu; Li Liu; Tsuyoshi Hamada; Keisuke Kosumi; Trevor Dutton; Lauren K Brais; Reiko Nishihara; Charles S Fuchs; Shuji Ogino; Matthew H Kulke
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.